Maxi Investments CY Ltd Takes Position in Stryker Corporation $SYK

Maxi Investments CY Ltd purchased a new position in shares of Stryker Corporation (NYSE:SYK) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 12,600 shares of the medical technology company’s stock, valued at approximately $3,967,000. Stryker makes up approximately 0.8% of Maxi Investments CY Ltd’s holdings, making the stock its 29th biggest position.

Other institutional investors have also recently added to or reduced their stakes in the company. Gables Capital Management Inc. bought a new stake in shares of Stryker in the 2nd quarter worth about $25,000. Kilter Group LLC bought a new position in Stryker during the 2nd quarter worth approximately $25,000. Godfrey Financial Associates Inc. bought a new position in Stryker during the 4th quarter worth approximately $26,000. Sankala Group LLC acquired a new position in shares of Stryker in the 4th quarter worth approximately $26,000. Finally, Compass Financial Management LLC bought a new stake in shares of Stryker in the 2nd quarter valued at approximately $27,000. 77.09% of the stock is owned by institutional investors and hedge funds.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Analysts Set New Price Targets

A number of equities analysts have commented on SYK shares. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a report on Friday, May 1st. Royal Bank Of Canada lowered their target price on Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a report on Friday, July 31st. BTIG Research dropped their price target on Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. BMO Capital Markets assumed coverage on Stryker in a research report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Stock Up 0.1%

SYK stock opened at $329.86 on Monday. The firm’s 50-day moving average is $326.99 and its two-hundred day moving average is $332.39. The company has a market capitalization of $126.52 billion, a price-to-earnings ratio of 34.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same period last year, the firm posted $3.13 earnings per share. The business’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Insider Buying and Selling at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. This represents a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 665,370 shares of company stock valued at $216,238,501. 4.60% of the stock is owned by corporate insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.